Introduction

Severe asthma occurs in 5–10% of asthmatic patients, with nasal polyposis as one of the most frequent comorbidity. Benralizumab was recently marketed, thus we could analyse its effects in real-life in severe asthma, and compare the effects of the drug in patients with and without polyposis.

Methods

Patients with severe asthma, receiving Benralizumab were enrolled in Italian asthma centres. The efficacy criteria for asthma (exacerbation rate, oral corticosteroid intake, hospitalizations, pulmonary function, exhaled nitric oxide) were evaluated at baseline and after 24 weeks of treatment. Patients were then sub-analysed according to the presence/absence of nasal polyposis.

Results

Fifty-nine patients with severe uncontrolled asthma (21 males, age range 32–78) and treated with benralizumab for at least 24 weeks has been evaluated, showing significant improvements in asthma-related outcomes, except for pulmonary function and exhaled nitric oxide. This included a reduction in the sino-nasal outcome-22 score versus baseline of 13.7 points (p = .0037) in the 34 patients with nasal polyposis. Anosmia disappeared in 31% patients (p = .0034). When comparing the groups with and without nasal polyposis, a similar reduction of exacerbations was seen, with a greater reduction of the steroid dependence in patients with polyposis (−72% vs −53%; p < .0001), whereas lung function was significantly more improved (12% vs 34%, p = .0064) without polyposis patients.

Conclusions

Benralizumab, after 6 months of treatment, confirmed its efficacy in severe asthma, and also in nasal polyposis, which is the most frequent comorbidity. The efficacy of Benralizumab in reducing steroid dependence was even higher in patients with polyposis.

中文翻译：

---

Benralizumab在现实生活中对重度哮喘的疗效，并以鼻息肉为重点。

介绍

严重哮喘发生在5-10％的哮喘患者中，鼻息肉病是最常见的合并症之一。Benralizumab最近上市，因此我们可以分析其在严重哮喘中的现实生活效果，并比较该药物在有无息肉病患者中的作用。

方法

接受贝拉利珠单抗治疗的严重哮喘患者进入意大利哮喘中心。在基线和治疗24周后评估哮喘的疗效标准（恶化率，口服糖皮质激素摄入，住院，肺功能，呼出气一氧化氮）。然后根据是否存在鼻息肉对患者进行亚分析。

结果

评估了59例严重的不受控制的哮喘患者（男性21例，年龄范围32-78），并接受贝那利珠单抗治疗至少24周，除肺功能和呼出的一氧化氮外，与哮喘相关的预后明显改善。这包括在34名鼻息肉病患者中，鼻窦结果22评分相对于基线降低了13.7分（p = 0.0037）。31％的患者失眠消失（p = .0034）。比较有鼻息肉病组和无鼻息肉组的情况，息肉病的发作率有类似的降低，息肉病患者类固醇依赖性的降低更大（-72％vs -53％； p <.0001），而肺功能显着没有息肉病患者的病情改善更多（12％vs 34％，p = .0064）。

结论

经过6个月的治疗，贝那珠单抗证实了其在严重哮喘以及最常见的合并症鼻息肉病中的功效。息肉病患者中贝那珠单抗降低类固醇依赖性的功效甚至更高。